Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MGLL | Q99685 | 7/20 | 0.54 |
| ▸ | TACR1 | P25103 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29446971 | 1.00 | MGLL (0.54) | MGLLTACR1ALDH1A1CYP2D6TSHR | |
| SCHEMBL19582601 | 0.89 | MGLL (0.53) | MGLLTACR1ALDH1A1CYP2D6TSHR | |
| SCHEMBL29417702 | 0.89 | MGLL (0.53) | MGLLTACR1ALDH1A1CYP2D6TSHR | |
| SCHEMBL20503512 | 0.87 | MGLL (0.56) | MGLLTACR1ALDH1A1 | |
| SCHEMBL25802812 | 0.87 | MGLL (0.56) | MGLL | |
| SCHEMBL20566495 | 0.82 | MGLL (0.49) | MGLLTACR1ALDH1A1 | |
| SCHEMBL30218709 | 0.82 | MGLL (0.49) | MGLLTACR1ALDH1A1 | |
| SCHEMBL19582699 | 0.81 | MGLL (0.56) | MGLL | |
| SCHEMBL19603397 | 0.81 | MGLL (0.46) | MGLLTACR1ALDH1A1CYP2D6TSHR | |
| SCHEMBL20168655 | 0.81 | MGLL (0.65) | MGLLTACR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3541820-B1 | MAGL INHIBITORS | H LUNDBECK AS (DK) | 2023-07-05 | — | — | EP | disclosed |
| EP-3541820-B1 | MAGL INHIBITORS | H LUNDBECK AS (DK) | 2023-07-05 | — | — | EP | disclosed |
| US-11691975-B2 | MAGL inhibitors | H. LUNDBECKA/S (DK) | 2023-07-04 | — | — | US | disclosed |
| US-11691975-B2 | MAGL inhibitors | H. LUNDBECKA/S (DK) | 2023-07-04 | — | — | US | disclosed |
| US-20220135563-A1 | MAGL INHIBITORS | H. LUNDBECK A/S (DK) | 2022-05-05 | — | — | US | disclosed |
| US-20220135563-A1 | MAGL INHIBITORS | H. LUNDBECK A/S (DK) | 2022-05-05 | — | — | US | disclosed |
| US-11059822-B2 | MAGL inhibitors | H. LUNDBECK A/S (DK) | 2021-07-13 | — | — | US | disclosed |
| US-11059822-B2 | MAGL inhibitors | H. LUNDBECK A/S (DK) | 2021-07-13 | — | — | US | disclosed |
| US-20200291023-A1 | MAGL INHIBITORS | H. LUNDBECK A/S (DK) | 2020-09-17 | — | — | US | disclosed |
| US-20200291023-A1 | MAGL INHIBITORS | H. LUNDBECK A/S (DK) | 2020-09-17 | — | — | US | disclosed |
| EP-3377060-B1 | PYRAZOLE DERIVATIVES, PROCESSES FOR THEIR PREPARATION AND USES THEREOF | LUNDBECK LA JOLLA RESEARCH CENTER INC (US) | 2020-08-19 | — | — | EP | disclosed |
| EP-3541820-A1 | MAGL INHIBITORS | Abide Therapeutics, Inc. (US) | 2019-09-25 | — | — | EP | disclosed |
| US-20190256494-A1 | PYRAZOLE COMPOUNDS AND METHODS OF MAKING AND USING SAME | H. LUNDBECK A/S (DK) | 2019-08-22 | — | — | US | disclosed |
| EP-3377060-A1 | PYRAZOLE COMPOUNDS AND METHODS OF MAKING AND USING SAME | Abide Therapeutics, Inc. (US) | 2018-09-26 | — | — | EP | disclosed |
| WO-2018093949-A1 | MAGL INHIBITORS | ABIDE THERAPEUTICS, INC. (US) | 2018-05-24 | — | — | WO | disclosed |
| WO-2018093949-A1 | MAGL INHIBITORS | ABIDE THERAPEUTICS, INC. (US) | 2018-05-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11059822-B2 | MAGL inhibitors | MAG, MAGI3, MGLL | MGLL 3/4885TACR1 375/4885ALDH1A1 4002/4885 |
| US-20220135563-A1 | MAGL INHIBITORS | MAG, MAGI3, MGLL | MGLL 3/4885TACR1 375/4885ALDH1A1 4002/4885 |
| US-20200291023-A1 | MAGL INHIBITORS | MAG, MAGI3, MGLL | MGLL 3/4885TACR1 375/4885ALDH1A1 4002/4885 |
| US-20190256494-A1 | PYRAZOLE COMPOUNDS AND METHODS OF MAKING AND USING SAME | ABHD6, ABHD16A, RABL6 | MGLL 21/4885TACR1 4556/4885ALDH1A1 1812/4885 |
| US-11691975-B2 | MAGL inhibitors | MAG, MAGI3, MGLL | MGLL 3/4885TACR1 375/4885ALDH1A1 4002/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.